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ABSTRACT: With 28 potential N-glycosylation sites, human carcinoem-
bryonic antigen (CEA) bears an extreme amount of N-linked glycosylation,
and approximately 60% of its molecular mass can be attributed to its
carbohydrates. CEA is often overexpressed and released by many solid tumors,
including colorectal carcinomas. CEA displays an impressive heterogeneity and
variability in sugar content; however, site-specific distribution of carbohydrate
structures has not been reported so far. The present study investigated CEA
samples purified from human colon carcinoma and human liver metastases and
enabled the characterization of 21 out of 28 potential N-glycosylation sites with
respect to their occupancy. The coverage was achieved by a multienzymatic
digestion approach with specific enzymes, such as trypsin, endoproteinase
Glu-C, and the nonspecific enzyme, Pronase, followed by analysis using
sheathless CE-MS/MS. In total, 893 different N-glycopeptides and 128 unique
N-glycan compositions were identified. Overall, a great heterogeneity was found both within (micro) and in between (macro)
individual N-glycosylation sites. Moreover, notable differences were found on certain N-glycosylation sites between primary
adenocarcinoma and metastatic tumor in regard to branching, bisection, sialylation, and fucosylation. Those features, if further
investigated in a targeted manner, may pave the way toward improved diagnostics and monitoring of colorectal cancer progression
and recurrence. Raw mass spectrometric data and Skyline processed data files that support the findings of this study are available in
the MassIVE repository with the identifier MSV000086774 [DOI: 10.25345/C5Z50X].
KEYWORDS: carcinoembryonic antigen, CEACAM5, glycosylation, colorectal cancer, glycopeptide, bottom-up proteomics, glycomics,
CE-MS
1. INTRODUCTION
With more than half of all secretory and cellular human proteins
being glycosylated, protein glycosylation is assumed to be the
most common and highly complex post-translational modifica-
tion (PTM).1 Glycoproteins play a role in an astonishing variety
of cellular processes, in particular, cell−cell interaction,
recognition, signaling, and adhesion processes on the cell
surfaces. For instance, protein N-glycosylation regulates and
fine-tunes critical immune response mechanisms and plays a
major role in tumor recognition and antitumor responses.2,3 An
assembly error, as minor as a single monosaccharide misplace-
ment, may strongly impact the function of a glycoprotein and, in
turn, the cell phenotype.4 Moreover, alterations of the N-glycan
profile can actively contribute to tumor development and
growth,5 as well as to the metastatic phenotype formation of the
tumor cells.6 Therefore, the common acceptance of glycans and
glycoproteins as cancer biomarkers is not surprising and keeps
driving the cancer glycomics field forward.7
Currently, various analytical platforms are being used to study
protein glycosylation. Among them, matrix-assisted laser
desorption ionization time-of-flight mass spectrometry
(MALDI-TOF-MS),8,9 and electrospray ionization mass spec-
trometry (ESI-MS), coupled online or off-line, with liquid
chromatography (LC)9,10 and capillary electrophoresis
(CE)11,12 show considerable popularity. In-depth site-specific
characterization of highly glycosylated proteins poses an extra
challenge for an analytical method that can only be well-resolved
on a glycopeptide level through bottom-up PTMmapping of the
enzymatic glycoprotein hydrolysates.13,14 Whereas LC-MS is an
acknowledged and well-established candidate for this task, CE-
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MS with a sheathless interface has advantages with respect to
sensitivity and analyte coverage in bottom-up LC-MS analysis of
glycopeptides.15,16 The excellent performance currently shown
by sheathless CE-MS is due to the specific design of a novel
interface that was first described by Moini.17 The use of this
interface for glycopeptide analysis has been successfully
demonstrated on moderately glycosylated proteins, paving the
way toward more complex glycopeptidome separations and
analysis.18,19
Human carcinoembryonic antigen (CEA) (UniProt entry
P06731, CEACAM5_HUMAN) is a highly N-glycosylated
protein of approximately 180 kDa with sugars accounting for
about half of its molecular mass.20 CEA can be found in normal
human colonic epithelial cells and is reported to be upregulated
in tumor forming and colonic adenocarcinogenic cell lines;21,22
elevated CEA levels are valued as a progression and outcome
biomarker in several forms of human cancers,23 including
colorectal cancer (CRC).24 Continuous measurement of CEA
serum levels is clinically used for the postoperative and post-
therapy recurrence monitoring of CRC patients. Nonetheless,
patients with no elevation of CEA in disease progression have
been shown to maintain these low levels in case of recurrence.25
Another study also demonstrated a poor predictive value and
low reliability of the CEA test for detecting treatable recurrences
at an early stage.26 The CEA test is also used for initial clinical
diagnostics of CRC, but its predictive value as a standalone
biomarker in cancer screening or detection proves rather poor.27
As CEA is predominantly produced by the tumor cells and has
been shown to tightly participate in the tumor metastatic
events,28 the expectation is that the overly abundant and
considerably heterogeneous glycosylation could be reflective of
cancer development and progression.While some attempts have
already been undertaken to profile CEA glycosylation and
analyze its relationship with cancer29−31 and other biological
processes,32 so far, its glycan structural and site-specific
heterogeneity in the cancer context has remained largely
unaddressed. Compared to the analysis of released N-glycans,
the bottom-up approach allows to characterize the protein N-
glycan pool with respect to the site occupancy. The same
considerations are also relevant to its biomarker potential, as
glycopeptides are gaining an increased attention in diagnostics
of cancer and other diseases and are investigated as target
substrates in cancer immunotherapy and immunodiagnos-
tics.33−35
In this study we used a sheathless CE-MS to analyze CEA N-
glycopeptides obtained after independent enzymatic digestions
with trypsin, endoproteinase Glu-C, and Pronase. CEA samples
retrieved from three different sources (two purified from human
colon carcinoma and one purified from human liver metastases)
were enzymatically hydrolyzed and subsequently analyzed by
sheathless CE-MS/MS. In total, 21 out of 28 potential N-
glycosylation sites, as well as their site-associated dominant N-
glycan sets could be identified. The comparison between colon
and metastatic CEA N-glycomes in terms of N-glycan classes
and their structural features hints toward different N-
glycosylation trends in primary and metastatic CRC tumors.
2. MATERIALS AND METHODS
2.1. Chemicals, Reagents, and Samples
All the chemicals were of analytical reagent grade or higher.
Proponan-2-ol (iPrOH), methanol (MeOH), ammonium
bicarbonate (ABC), and sodium hydroxide (NaOH) were
purchased from Merck (Darmstadt, Germany). Water (LC-MS
grade), acetonitrile (MeCN) (LC-MS grade), glacial acetic acid
(HAc), hydrochloric acid (HCl), DL-dithiothreitol (DTT),
iodoacetamide (IAA), ammonium acetate (NH4Ac), formic acid
(FA), TPCK-treated trypsin from bovine pancreas, and Pronase
from Streptomyces griseus were purchased from Sigma-Aldrich
(Steinheim, Germany). Endoproteinase Glu-C from Staph-
ylococcus aureus V8 was supplied by Promega Corporation
(Madison, WI, USA). CEA purified from human colon
carcinoma was obtained from MyBioSource, Inc. (CEA1; San
Diego, CA, USA) and Fitzgerald Industries International
(CEA2; Acton, MA, USA). CEA purified from human liver
metastases of colorectal carcinoma cells was obtained from Lee
BioSolutions, Inc. (CEA3; Maryland Heights, MO, USA).
2.2. Digestion of CEA
Equal amounts of each CEA sample (10 μg) were taken for all
the digestion procedures and diluted with 10 μL of 25 mM ABC
buffer (1 μg/μL of protein). The protein disulfide bridges were
reduced with 1 μL of 22mM(tryptic) or 55mMDTT (Glu-C or
Pronase) for 30 min at 60 °C. After the sample was cooled to
room temperature, 1 μL of 72 mM (tryptic) or 180 mM IAA
(Glu-C or Pronase) was added. After addition of the alkylation
reagent the samples were left in the dark for 30 min. Prior to
adding the enzyme to the sample, the reaction was inhibited with
1 μL of 78 mM DTT and left for 30 min at room temperature.
TPCK-treated trypsin (0.5 μg/μL), Glu-C (0.2 μg/μL) or
Pronase (0.2 μg/μL) was added to the sample in an
enzyme:substrate ratio of 1:10 w/w (trypsin) or 1:20 w/w
(Glu-C and Pronase). Finally, incubation was performed
overnight at 37 °C. Each enzymatic digestion was performed
once for each CEA sample.
2.3. Sheathless CE-MS/MS
CE experiments were carried out on a SCIEX/Beckman Coulter
CESI 8000 system (SCIEX, Framingham, MA) equipped with a
temperature-controlled sample tray and a power supply
delivering up to 30 kV. A 91 cm long (LT) × 30 μm i.d. × 150
μm o.d. bare fused-silica capillary (Silica Surface OptiMS
cartridge, SCIEX) with the high sensitivity porous sprayer in the
outlet tip was used for all the separations. A 10% v/v HAc water
solution (pH 2.3) was used as a background electrolyte (BGE).
Prior to each sample injection, the capillary was rinsed at
pressure of 5 psi with 0.1MNaOH (2.5 min), water (4 min), 0.1
M HCl (2.5 min), water (4 min), and BGE (4 min). An online
sample preconcentration by transient isotachophoresis (t-ITP)
was achieved by diluting the CEA digests to a final concentration
of 100 mM NH4Ac at pH 4.0, which acted as a leading
electrolyte solution (final concentration of digested protein 0.40
μg/μL).36 Samples were hydrodynamically injected in three
different amounts: 1 psi for 60 s, 5 psi for 60 s and 8 psi for 60 s.
In all experiments, sample injection was preceded by a water dip
and followed by a postplug BGE injection (both at 0.5 psi for 25
s) to enhance t-ITP stacking and to prevent sample loss. A
separation voltage of 20 kV (normal polarity, anode at the
capillary inlet) was applied for all electrophoretic separations,
the temperature was set for 25 °C.Multiple analysis (n = 3) were
carried out for every digested CEA sample per injected volume.
The CE instrument was hyphenated to an Impact HD UHR-
QqTOF-MS (Bruker Daltonics, Bremen, Germany) via a CESI
OptiMS Bruker MS adapter kit (SCIEX) that allowed an
optimal positioning of the capillary porous tip in front of the
mass spectrometer nanospray shield (Bruker Daltonics). All
experiments were carried out using dopant enriched nitrogen
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gas (DEN-gas).19 For this purpose, an in-house made polymer
cone was slid onto the housing of the porous tip, allowing for a
coaxial sheath flow of the DEN-gas around the nano-ESI emitter
(MeCN was used as a dopant). Under optimized conditions,
CE-MS/MS experiments were carried out in ESI positive mode
using the following parameters: glass capillary voltage at 1200 V,
drying gas temperature at 150 °C, drying gas flow rate at 1.2 L/
min, nebulizer gas pressure at 0.2 bar, quadrupole ion energy at
3.0 eV and collision cell energy at 7.0 eV. MS data was acquired
between m/z 200 and 2000 with a spectral acquisition rate of 1
Hz. MS/MS spectra were acquired in a data dependent mode
with an absolute threshold of 4548 counts and active exclusion.
Specific m/z values that were already acquired three times were
excluded and released after 0.8 min, unless the precursor had a
five times higher intensity than the observed in the previous
acquisitions. Raw CE-MS/MS data are available via the
MassIVE repository with identifier MSV000086774 [DOI: 10.
25345/C5Z50X].
2.4. Data Analysis
Manual interpretation of CE-MS/MS spectra were performed in
DataAnalysis 4.3 (Bruker Daltonics, Build 110.102.1532). All
mass spectra were recalibrated internally with sodium acetate
clusters detected at the beginning of the electrophoretic runs.
Carbohydrate moieties of the N-glycopeptides were deduced
from the fragmentation spectra by manual annotation on the
basis of general glycan fragmentation rules37 and/or basic rules
of the N-glycan biosynthetic pathway.38 Glycoforms were
labeled with glycan net compositions specifying number of
hexoses (Hex), N-acetylglucosamines (HexNAc), fucoses
(Fuc), and N-acetylneuraminic acids (NeuAc); these mono-
saccharide abbreviations will be further used throughout this
manuscript. Exemplary annotations of MS/MS N-glycopeptide
spectra are provided in Supporting Information, Figure S1. N-
Glycopeptides were included based upon their exact mass (±10
ppm), signal-to-noise (S/N; >9), and migration order. Briefly,
all MS/MS scans were screened for oxonium ions (m/z 204.087,
366.140, and 292.103, singly charged HexNAc1, Hex1HexNAc1,
and NeuAc1 fragments, respectively). The peptide mass was
deduced by subtracting 203.079 (neutral loss of HexNAc) from
the characteristically intense Y1 ion (corresponding to [peptide
+ HexNAc + H]+) and then matched against in silico digests of
CEA (trypsin and Glu-C) to determine the amino acid sequence
and N-glycosylation site position. In addition, the presence of
low-intensity peptide b-ions was used to further confirm the
amino acid sequence. The glycan composition could be assigned
based upon the presence of other Y-ions in the spectra as well as
by the neutral loss of (combined) monosaccharides from the
precursor mass. In case of Pronase, deduced peptide Mr values
Figure 1. Experimentally observed linearity of electrophoretic behavior exemplified with N-glycopeptides sharing ITPNNNGTYACFVSNLATGR
peptide backbone (N-glycosylation site N650). Experimental migration times of theN-glycopeptides in the electropherogram (A) were fitted to a linear
regression line (B) with the classical polymer semiempirical model (q/Mr
1/2).40 The table (C) showcases theoretical Mr, q, and q/Mr
1/2 values and
experimentally obtained migration time values, which are proportional to me. Blue square: N-acetylglucosamine (N), green circle: mannose (H),
yellow circle: galactose (H), red triangle: fucose (F), pink diamond: N-acetylneuraminic acid (S).
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were matched to theoretical Mr values of randomly cleaved
peptides from CEA generated by the FindPept tool (http://
www.expasy.org/tools/findpept.html, with a mass accuracy
value of 10 ppm).39 Through introducing some minor
adaptations of the default data processing pipeline of Skyline
software (MacCoss Lab Software, version 20.1.0.76), non-
fragmented N-glycopeptides in the MS1 spectra were identified
as well as to confirm the identity of the manually annotated
fragmented species. Briefly, all MS/MS-confirmed glycan
compositions, their expected derivatives inferred from the N-
glycan biosynthetic pathway and extra glycan species found in
the glycoprofile of tumor-associatedCEA in the literature29 were
loaded into Skyline software as possible modifications for all the
samples (in total 128 compositions (Supporting Information,
Table S1), 89 of these were MS/MS-confirmed by at least one
glycopeptide in at least one sample type (CEA1, CEA2, or
CEA3)). In addition, a peptide mass list was created for every
identified peptide backbone of every manually detected N-
glycopeptide. Upon the basis of this mass list in combination
with all possible glycan compositions, a full assignment was
provided by Skyline for the tryptic and Glu-C digestions. Within
a single data processing step, improved peak assignment and
quantification of the relative peak area of all compounds could
be achieved with Skyline. All assigned N-glycopeptides by
Skyline were visually evaluated based upon peak shapes of the
detected protonated molecular ions of a compound, ppm error
(±10 ppm) as well as on the fitness and quality of the isotopic
patterns (dot product value >0.8), only those that passed these
criteria were chosen for quantitation. After this, generated peak
areas were normalized per sample and perN-glycosylation site to
obtain their relative abundances (percentage of all glycoform
peak areas detected per site); these values were used for further
analyses and visualization. Despite Skyline software tool not
being primarily designed for glycopeptide profiling and
annotation, its above-mentioned features appeared to be very
useful for this application. Within a single data processing step
Skyline can improve peak assignment and quantify the relative
area of all compounds. All resulting N-glycopeptides were
supplied with a graphical structural representation of the
attached glycan (Supporting Information, Tables S2 and S3).
A representation of the glycopeptide annotation and quantita-
tion pipeline highlighting the Bruker DataAnalysis and Skyline
software environments and features are shown in Supporting
Information, Figure S2. Skyline processed data are available via
the MassIVE repository with identifier MSV000086774 [DOI:
10.25345/C5Z50X].
3. RESULTS AND DISCUSSION
3.1. Analysis of CEA N-Glycopeptides by Sheathless
CE-MS/MS
CEA N-glycopeptides were generated using three different
proteases and analyzed by CE-MS/MS. Representative
extracted ion electropherograms (EIEs) of severalN-glycoforms
related to N-glycosylation site N650 (tryptic peptide backbone
ITPNNN650GTYACFVSNLATGR) are illustrated in Figure 1A.
A broad range of glycans was observed varying in the overall
composition of monosaccharide units, their structural assembly
and charge (presence of terminal NeuAc). The glycan portions
Figure 2. Human carcinoembryonic antigen (CEACAM5_HUMAN) sequence. Putative N-glycosylation sites are indicated in bold red.
Glycopeptides that were detected after specific proteases digestion are highlighted in green (Glu-C) and orange (trypsin). The glycopeptide coverage
by a nonspecific protease (Pronase) digestion is shown in blue. The total molecular mass of the glycosylated protein is reported to vary between
150 000 and 200 000 Da; the mass calculations are based on the most prominent mass (180 000 Da).21
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were found to strongly affect the electrophoretic mobility of the
N-glycopeptides. The number of negatively charged NeuAc
units determined the formation of distinct glycoform clusters
per peptide backbone. Semiempirical models can be used to
relate themolecular mass (Mr) and the charge (q) of a peptide to
its electrophoretic mobility (me) and to predict the electro-
phoretic migration behavior. Recently, it has been shown that
the classical polymer model in which q/Mr
1/2 is proportional to
me can be applied to predict the electrophoretic mobility of N-
glycopeptides.40 An illustration of this model is shown in Figure
1C, where for a range ofN-glycoforms the theoreticalMr, q, and
q/Mr
1/2 values are provided next to their experimentally
obtainedmigration time values, which are inversely proportional
to me. The relationship observed between migration times and
q/Mr
1/2 was in accordance with the classical polymer model
(Figure 1B). By investigating these models, structural
modifications, charge characteristics and conformations of
peptides can be studied. In our study these plots were
constructed for all the detected N-glycoforms with the same
peptide backbone as a sanity check of the glycopeptide structure
assignment which was primarily based on MS/MS data.
3.2. Sequence Coverage and Characterization of CEA
(Glyco)Peptides
Figure 2 shows the amino acid sequence of CEA and its potential
28N-glycosylation sites (marked in bold red). In addition to the
numerous N-glycosylation sites, CEA was expected to have a
considerable heterogeneity in the sugar content per site of the
protein, hence the analysis and structural elucidation of N-
glycopeptides from CEA enzymatic digests was not straightfor-
ward. Taking these factors into account, digestion with several
proteases or mixtures of proteases was considered, as it was
previously demonstrated to increase sequence coverage and
improve the PTM characterization.41,42 Three different
proteolytic enzymes were used to generate three distinct protein
digests for each CEA sample. Trypsin and Glu-C are specific
serine proteases that cleave C-terminal peptide bonds of lysine
(K) and arginine (R), or aspartic (D) and glutamic acid (E),
respectively. Spectra of the MS/MS analysis of trypsin and
Glu-C digests are often sufficient to characterize moderately
glycosylated proteins.41 In particular, Glu-C is able to generate
the peptide backbones that are less likely to be covered by
trypsin, as the trypsin-specific cleavage sites that have D and E
amino acids in close proximity to R amino acid have lower
probability of being hydrolyzed.43 However, the abundant
glycosylation on CEA may account for inefficient cleaving in
PTM-rich protein regions and large glycopeptides with multiple
glycosylation sites, thereby impairing the annotation. Another
issue are the nonglycosylated peptides in proteolytic digests
suppressing the glycopeptide ionization in ESI-MS and leading
to substantial sensitivity reduction for glycopeptides.41
Pronasea nonspecific mixture of proteolytic enzymeswas
reported to help in circumventing these limitations.44 Pronase
produces smaller peptide moieties (typically 1 to 8 amino acids)
and usually cleaves nonglycosylated peptides to single amino
acids, which reduces signal suppression of N-glycopeptides.45
However, since nonspecific proteases generate peptides rather
haphazardly, CE-MS/MS data sets from Pronase digests were
harder to interpret and, most importantly, the resulting N-
glycopeptides could not be reliably quantified. Therefore, these
N-glycopeptides were viewed from an exploratory perspective
only, namely for providing a better overview of the total
glycoprofile and enriching the putative modifications list. When
combining the information obtained with the different enzymes,
21 out of the potential 28 N-glycosylation sites were covered.
These peptide backbones are highlighted on the CEA sequence
in Figure 2. Some very short N-glycopeptides from Pronase
digests were annotated (Supporting Information, Table S3) but
not mapped, due to the lack of specificity of the sequence motif
and could be assigned to multiple glycosylation sites. Addition-
ally, the peptide mass fingerprint data of all samples were
searched against the human Uniprot database with Mascot
Daemon (v.2.5.1, Matrix Science); the resulting peptide
coverage is illustrated in Supporting Information, Figure S3).
Albeit the total peptide coverage appears to be rather low, this
could be explained by the high glycosylation degree of CEA. The
Mascot matching algorithm is not designed to map glycosylated
peptides, moreover, glycans are likely to cause steric hindrance
for the proteases attempting to reach the cleavage site. From
Glu-C digests a rather long peptide (Ala174−Asp227) was found
as an unmodified sequence only, although it is harboring N-
glycosylation specific sequons some of which are glycosylated
and characterized from our other data sets (e.g., Pronase
digests). That underscored the proteoform variability in N-
glycosylation for these sites, i.e., a certain portion of the
glycoprotein does not bear glycan modifications on these
putative sites.
3.3. Site-Specific N-Glycoprofile of CEA
Supporting Information, Table S2 represents all the discovered
N-glycopeptides that were quantified (trypsin and Glu-C
digestion) and Supporting Information, Table S3 provides
Figure 3.Relative abundances of the 10most abundant glycoforms of the quantitatively characterizedN-glycosylation site N204/560 (CEA1 is plotted in
blue, CEA2 in green and CEA3 in orange). Peak area values were normalized by N-glycosylation site for all samples (as percentage of all glycoforms
peak areas detected per site). The top 10most abundant glycoforms of allN-glycosylation sites quantitatively characterized can be found in Supporting
Information, Figure S4. Error bars indicate the standard deviation. H: hexose, N: N-acetylhexosamine, F: fucose and S: N-acetyl neuraminic acid.
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those that were only structurally characterized (Pronase
digestion), all grouped by N-glycosylation site for the three
CEA samples. To ease the interpretation of the trends in
differential N-glycosylation patterns and structural features of
the glycoprofiles, glycosylation traits (namely glycosylation type,
as well as antennarity, fucosylation, and sialylation present on all
glycans (total) and within the complex types (complex)) were
mathematically derived from the data sets with relative
abundance values (Supporting Information, Figure S4, derived
traits calculation is provided in Supporting Information, Table
S4). Moreover, to obtain a better representation of the most
characteristic N-glycan species, the top 10 N-glycans (based
upon their relative abundance) were selected per quantifiableN-
linked glycosylation site and plotted as histograms in Figure 3
and Supporting Information, Figure S5.
Overall, the tryptic digestion allowed the identification of a
total number of 489 different N-glycopeptides across the three
CEA sample types, corresponding to eight N-glycosylation sites
(N197/N553, N204/N560, N375, N580, N650, and N665). Unfortu-
nately, no differentiation could be made between N-glycopep-
tides belonging to sites N197 and N553 or N204 and N560, as they
presented the same peptide sequences after digestion with
trypsin (LQLSNGN197/553R and TLTLFN204/560VTR, respec-
tively). SomeN-glycosylation sites were expected, but not found
in the data (e.g., N152, N208, N246, N480). This may be caused by
glycans shielding the theoretical tryptic cleavage sites, which
resulted in large peptide moieties (aa ≥ 20). Furthermore,
certain peptide sequences carried several potential N-glyco-
sylation sites. Hence, if all of these sites were occupied, the
complexity of the glycopeptide would complicate the detection
and identification of these sites. Interestingly, site N197/553 was
represented as two charge variants: LQLSNGN197/553R and its
deamidated version; LQLSDGN197/553R, which has not been
reported yet. It is well-known that asparagine (N) can undergo
spontaneous deamidation both in vivo and in vitro and the rate
increases under temperature and pH typical for tryptic
digestion.46 Therefore, this modification could happen as a
result of peptide degradation during sample preparation.
However, no other asparagine degradation was observed for
(glyco)peptides in any of the samples. The peak areas and
shapes, observed for both charge variants, were quite similar in
value and appearance, and they migrated one after another as
expected. Moreover, the glycan subsets of the charge variants
overlapped significantly, but not fully (Supporting Information,
Table S2 and Figure S5). Taking into account that the peptide
sequence is shared between the two N-glycosylation sites, it was
possible to assume that the two peptides originated from
different parts of the protein, but further research is needed to
confirm this suggestion.
The Glu-C digest resulted in 150 uniqueN-glycopeptides and
yielded the identification of three additional N-glycosylation
sites (N152/N508, N466) compared to the tryptic digest and
overlapped in one site (N580). However, two of these sites
(N152/N508) could not be reliably quantified due to peptide
backbone variability from the nonspecific Glu-C cleavages
(Supporting Information, Table S3). Interestingly, the site that
was detected in both trypsin and Glu-C digests (N580), revealed
much less glycoforms in the trypsin data than in the Glu-C data
(albeit fully overlapping). This further points toward the
possible interference of abundant and bulky N-glycan
Figure 4. Schematic representation of human carcinoembryonic antigen (CEACAM5_HUMAN) domain structure with the N-glycosylation sites
revealed by this study marked for the different type of CEA samples. The CEA domains are depicted as barrels and N-glycosylation sites (shown as
double dots) are mapped along the structure. The black double dots are identifiedN-glycosylation sites in this study (tryptic or Glu-C digest) and are
supplied with the most abundant N-glycan composition per all three types of CEA analyzed (side panels). The N-glycans highlighted in orange (N197
and N553) and in green (N204 and N560) share the same peptide backbone, hence the discovered glycan populations are shared. Confidently
characterized by nonspecific digestion data sites are shown as red double dots (Pronase) and are not accompanied by the most abundant glycan
structures due to the lack of reliable quantification. Undiscovered N-glycosylation sites are shown as gray double dots. All identified N-glycopeptides
can be found in Supporting Information, Table S2 (quantified) and S3 (nonquantified)). Blue square:N-acetylglucosamine (N), green circle: mannose
(H), yellow circle: galactose (H), red triangle: fucose (F), pink diamond: N-acetylneuraminic acid (S).
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modifications with the performance of certain enzymes, in line
with literature.43,47
With regard to Pronase, the digests revealed in total of 254N-
glycopeptides. Due to the nonspecificity of the enzyme, a partial
overlap in coverage was found between the Pronase generated
N-glycopeptide pool and the glycopeptide sets produced by the
specific enzymes. Nonetheless, 10 new sites were confirmed
(N104, N208, N256, N274, N330, N351, N432, N480, N529, N612) and
Pronase digest contributed to the characterization of 21 N-
glycosylation sites in total.
Throughout the identified and quantified N-glycosylation
sites, different classes of N-glycans were observed on the same
site, including some high-mannose and hybrid types but mainly
complex structures (bi-, tri-, and tetra-antennary structures).
Some nonquantifiable sites (N152/508, N351, N256 in Supporting
Information, Table S3) appeared to be populated only with
high-mannose type structures. The rest of identified N-
glycopeptides from nonquantifiable data were a mixture of
different N-glycan types, though the majority of these were
strongly overlapping in sequence position. Therefore, more
high-mannose only sites could exist on the CEA structure.
Figure 4 gives an overview of the site-specific N-glycosylation
of the three CEA samples. The overall resulting N-glycosylation
site coverage is rather comprehensive, albeit the B1 protein
domain was covered quite poorly. From the Pronase digest,
small high-mannose type glycoforms structures could be
assigned to this sequence area (Supporting Information, Table
S3), which is most likely caused by steric hindrance from the
glycans shielding binding site for the specific proteases. Figure 4
gives theN-glycan structures with the highest relative abundance
per CEA sample analyzed. The N-glycosylation sites (indicated
in red) are covered from the Pronase digests and, as these could
not be reliably quantified, were not accompanied by the most
abundant glycan structures. Visual evaluation prompts two
outcomes: distal part (C-terminal) area of CEA is easier to reach
by specific proteolytic enzymes and it harbors more potential
differential traits of increasing malignancy potential of the tumor
cells. In particular, the highest levels of fucosylation and,
especially, sialylation, were observed for the liver metastases
CEA sample (CEA3), which presented a higher degree of
metastatic involvement (Figure 3 and Supporting Information,
Figures S4 and S5).
Looking closer at the overallN-glycan population for the three
different types of CEA samples analyzed, a characteristic cancer
glycosylation pattern emerges. To start with, a notable
expression of truncated/paucimannosidic and high-mannose
structures was observed in all three sources analyzed in this
study. This feature is hypothesized to raise from incomplete N-
glycan processing in the early stage of CRC.48,49 As could be
seen from the glycosylation type panels in Supporting
Information, Figure S4, the location of these structures has no
predilection toward any particular area of the protein. Despite
the vast presence of incomplete structures, they are not very
abundant and moderately contribute to the overall CEA
glycoprofile.
Bisection and branching appear to have a controversial role in
cancer glycobiology. A fair amount of bisecting complex-type
structures represents an advantage in immune evasion and
metastatic potential50 and impacts several cancer-assisting
biological pathways.51 Increased branching is also viewed as
both cancer-associated and oncogenesis-promoting.48,51 It is
widely accepted that high bisection levels are likely to coincide
with low degrees of branching as bisecting GlcNAc expression is
governed by GNT3 enzyme that effectively inhibits the activities
of other GlcNAc transferases.52 Surprisingly, this study revealed
that both branching and bisection levels are relatively high in all
CEA samples and particularly high for CEA3 (liver metastasis).
Furthermore, in many cases both features were combined within
the same glycan structure which, to the best of our knowledge, is
uncommon for cancer-related phenotypes or CEA glycosylation
features.29 Notable differences in antennarity between primary
colon carcinoma (CEA1 andCEA2) andmetastatic tumor tissue
(CEA3) samples were found on sites N204/560, N375, N466, N650
and N655 (Supporting Information, Figure S4). Peculiarly, while
it is typical for mammalian cells to terminate GlcNAc residues
with galactose units, the detected highly branched tetra-
antennary structures often had their antennae only partially
occupied by galactose (i.e., incomplete galactosylation),
indicating lowered levels of substrate or β4GalT enzyme
dysregulation. Similar findings of lowered galactosylation in
tumor-associated CEA N-glycome were obtained before, by
lectin microarray analysis, and the authors speculated about its
role in immune response involving CEA.53 The same study also
reported overall increased levels of GalNAc in tumor-associated
CEA, which could also explain and/or contribute to under-
galactosylation of antennae. Alongside with high branching,
CEA N-glycans showed proclivity toward (poly-)LacNAc
elongation on highly branched structures, which is also a
known CRC feature associated with poor prognosis.48 This
signature difference between primary and metastatic samples is
the most notable in the most distal part of CEA sequence (sites
N650 and N655) and is not reflected much along the other sites.
Sialylation changes are commonly found in cancer biology
and have potential for diagnosis and therapy.54−56 Particularly,
increased sialylation has often been associated with cancer
invasiveness, and elevated serum total sialylation (TSA), and
particularly high level of sialylation were found for liver
metastases.57,58 Induced by dysregulation of sialidases and
sialyltransferases aberrant NeuAc patterns play a role in immune
evasion and cancer associated inflammation. CRC is no
exception, as increased sialylation is shown to contribute to
postoperative recurrence,59 therapeutic resistance and meta-
static spread.60 The CEA samples exhibited an overall moderate
degree of sialylation (even highly branched N-glycans never
harbored more than two NeuAcs), while elevated sialylation
levels were found for the CEA3 sample on sites N204/560, N375,
N580, N650, and N665 (Supporting Information, Figure S4). Total
sialylation was rather in line with complex-type sialylation levels
indicating low contribution of hybrid-type N-glycans in the
overall sialylation pool. NeuAc modifications (e.g., methylation,
acetylation and sulfation) were not included in the scope of this
work. It is also worth mentioning that NeuAc linkage isomers
(α-2,3 and α-2,6 and α-2,9 variants) were proven to be an
important discriminatory trait in several cancers, including
CRC.60 In this study, no NeuAc linkage information could be
obtained, but, acknowledging the importance of the trait,
experimental considerations for linkage specificity evaluation
will be included in follow-up research.
Amid the glycan traits discussed above and illustrated in
Supporting Information, Figure S4, fucosylation was the most
striking feature of the CEA N-glycome in the analyzed samples.
Aberrant increase in fucosylationarising from a large pool of
GDP-fucose donors, abnormal expression of enzymes, and
substrate availabilityis reputed to be a red flag in many
oncological diseases (brain, colorectal, breast, liver, lung, and
other cancers) and it is involved in multiple stages of cancer
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biology (proliferation, survival, multidrug resistance, invasion
and metastasis) and sustained inflammatory processes.61,62
Whereas upregulation of core fucosylation (governed by FUT8
enzyme overexpression) has been reported to directly promote
epithelial-mesenchymal transformation (EMT) and dediffer-
entiation (i.e., metastatic potential),62 terminal fucosylation is
partaking in the generation of Lewis antigens. Upon interaction
with certain selectins, Lewis type antigens (on both immune
cells and especially cancer cells) promote angiogenesis, reform
tumor microenvironment, and, paradoxically, enhance cancer
progression via chronic activation of innate immune cell.
Additionally, elevated fucose levels are linked to the cancer
cell stemness. The possible roles of fucosylated antigens in
cancer biology were recently reviewed by Blanas and colleagues
in full details.63 Sialyl-Lewis antigens (sialylated version of Lewis
antigens) are also impacting the CRC progression on multiple
stages of development.48 However, these will not be engaged in
the current discussion due to rather moderate partaking of
sialylation in the CEA glycoprofiles observed in this study. CEA-
associated-glycan pool observed in this study appeared to be
overabundantly fucosylated with regards to both core and
terminal fucosylation: on average about half of all glycans from
all quantifiable N-glycosylation sites carried at least one fucose.
The maximum number of fucose monosaccharides in a single
glycan composition could reach up to seven units. As an
illustration, the MS/MS-confirmed structure in H9N8F7S1 on
site N204/560 (CEA3 sample, Supporting Information, Table S2)
can be revised. Interestingly, almost all N-glycans associated
with the sites N204/560 and N466 carried at least one fucose within
the structure regardless of the CEA source. Nonetheless,
Supporting Information, Figure S4 demonstrate that, on
average, the CEA3 sample exhibits a higher level of fucosylation
than CEA1 and CEA2, when considering both the abundances
of fucosylated glycans as well as number of fucose units per
glycans. That is particularly evident for sites N375, N580, andN650,
where primary tumors showed significant levels of non-
fucosylated N-glycan species. Moreover, for sites N204/560 and
N466 of the CEA3 sample a higher amount of fucosylated
determinants and oligofucosylated N-glycans was observed
accounting for more Lewis antigens.
Overall, notable differences in one or more of the analyzedN-
glycan traits perN-glycosylation site could be observed per CEA
sample type (primary tumor vs metastatic site; Figure 3,
Supporting Information, Figures S4 and S5).
4. CONCLUDING REMARKS
In this study, CEA N-glycosylation sites were characterized
usingN-glycopeptide profiles obtained after enzymatic digestion
with trypsin, Glu-C, and Pronase and analysis by sheathless CE-
MS/MS. Complementary information was obtained through the
use of the three above-mentioned enzymes, hence allowing an
improvedN-glycosylation site coverage and the identification of
most of the potential N-glycosylation sites (21 out of 28), their
degree of occupancy, and their site-specific dominant N-glycan
types (893 different N-glycopeptide glycoforms were identified
with a total of 128 unique glycan compositions). Overall, the
CEA N-glycoprofile follows the previously reported cancer-
associated patterns, while exhibiting its distinct features:
simultaneous increased bisection and branching, incomplete
galactosylation or (poly)LacNAc elongation on highly branched
structures, moderate levels of sialylation, and extremely high
levels of fucosylation. For a better understanding of CEA
glycosylation pattern heterogeneity, and to confirm our findings,
an average glycosylation profile using a glycomics approach
could be explored in the foreseeable future. Nonetheless, the N-
glycome profile seems to be a less promising source of
biomarkers. This is especially due to the low abundance of
CEA and high abundance of other glycoproteins present in
complex biological samples that may skew the obtained N-
glycome profiles of CEA, even for immunopurified samples. It
should be noted that this study presents an exploratory
perspective on the N-glycosylation heterogeneity of CEA, and,
due to the small sample set, only initial observations about the
biological differences in glycosylation between primary and
metastatic CRC can bemade. These findings should be validated
on a larger set of samples to establish novel biomarkers. To bring
an example, the distal part of the CEA sequence (sites N580, N650,
N655 from tryptic digest, and site N466 from Glu-C digest)
exhibits the most potential in tumor biological status
discrimination (colon primary carcinoma versus liver meta-
stases) with regards to bisection, antennarity, fucosylation, and
sialylation traits. The presented multienzyme sheathless CE-
MS/MS bottom-up strategy shows potential to provide
important biologic information on how N-glycosylation may
influence CEA processing in cancer biogenesis. Furthermore,
this approach may be successfully translated to the character-
ization of other highly glycosylated and complex endogenous
glycoprotein biomarkers or glycoprotein biopharmaceuticals.
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(43) Šlechtova,́ T.; et al. Insight into Trypsin Miscleavage:
Comparison of Kinetic Constants of Problematic Peptide Sequences.
Anal. Chem. 2015, 87 (15), 7636−43.
(44) Lee, J.; et al. Designation of fingerprint glycopeptides for targeted
glycoproteomic analysis of serum haptoglobin: insights into gastric
cancer biomarker discovery.Anal. Bioanal. Chem. 2018, 410 (6), 1617−
1629.
(45) Zauner, G.; et al. Protein glycosylation analysis by HILIC-LC-
MS of Proteinase K-generatedN- andO-glycopeptides. J. Sep. Sci. 2010,
33 (6−7), 903−910.
(46)Hao, P.; Ren, Y.; Alpert, A. J.; Sze, S. K. Detection, Evaluation and
Minimization of Nonenzymatic Deamidation in Proteomic Sample
Preparation. Mol. Cell. Proteomics 2011, 10 (10), O111.009381.
(47) Proc, J. L.; et al. AQuantitative Study of the Effects of Chaotropic
Agents, Surfactants, and Solvents on the Digestion Efficiency of Human
Plasma Proteins by Trypsin. J. Proteome Res. 2010, 9 (10), 5422−5437.
(48) Holst, S.; Wuhrer, M.; Rombouts, Y. Glycosylation Character-
istics of Colorectal Cancer. Adv. Cancer Res. 2015, 126, 203−256.
(49) Sethi, M. K.; et al. In-depth N-glycome profiling of paired
colorectal cancer and non-tumorigenic tissues reveals cancer-, stage-
and EGFR-specific protein N-glycosylation. Glycobiology 2015, 25
(10), 1064−1078.
(50) Lee, L. Y.; et al. Comprehensive N-Glycome Profiling of
Cultured Human Epithelial Breast Cells Identifies Unique Secretome
N-Glycosylation Signatures Enabling Tumorigenic Subtype Classi-
fication. J. Proteome Res. 2014, 13 (11), 4783−4795.
(51) Pearce, O. M. T. Cancer glycan epitopes: biosynthesis, structure
and function. Glycobiology 2018, 28 (9), 670−696.
(52) Taniguchi, N.; Kizuka, Y. Glycans and cancer: role of N-glycans
in cancer biomarker, progression and metastasis, and therapeutics. Adv.
Cancer Res. 2015, 126, 11−51.
(53) Zhao, Q.; Zhan, T.; Deng, Z.; Li, Q.; Liu, Y.; Yang, S.; Ji, D.; Li, Y.
Glycan analysis of colorectal cancer samples reveals stage-dependent
changes in CEA glycosylation patterns. Clin. Proteomics 2018, 15, 9.
(54) Bull, C.; et al. Targeting aberrant sialylation in cancer cells using a
fluorinated sialic acid analog impairs adhesion, migration, and in vivo
tumor growth. Mol. Cancer Ther. 2013, 12 (10), 1935−46.
(55) Hao, C.; Zhang, G.; Zhang, L. Serum CEA levels in 49 different
types of cancer and noncancer diseases. Prog. Mol. Biol. Transl Sci. 2019,
162, 213−227.
(56) Pearce, O. M.; Laubli, H. Sialic acids in cancer biology and
immunity. Glycobiology 2016, 26 (2), 111−28.
(57) Plucinsky,M. C.; et al. Total and lipid-associated serum sialic acid
levels in cancer patients with different primary sites and differing
degrees of metastatic involvement. Cancer 1986, 58 (12), 2680−5.
(58) Vajaria, B. N.; et al. Sialylation: an Avenue to Target Cancer
Cells. Pathol. Oncol. Res. 2016, 22 (3), 443−7.
(59) Park, J. J.; Lee, M. Increasing the alpha 2, 6 sialylation of
glycoproteins may contribute to metastatic spread and therapeutic
resistance in colorectal cancer. Gut Liver 2013, 7 (6), 629−41.
(60) Sethi, M. K.; et al. Comparative N-glycan profiling of colorectal
cancer cell lines reveals unique bisecting GlcNAc and alpha-2,3-linked
sialic acid determinants are associated with membrane proteins of the
more metastatic/aggressive cell lines. J. Proteome Res. 2014, 13 (1),
277−88.
(61) Li, J.; et al. Unmasking Fucosylation: from Cell Adhesion to
Immune System Regulation andDiseases.Cell Chem. Biol. 2018, 25 (5),
499−512.
(62) Shan, M.; et al. Fucosylation in cancer biology and its clinical
applications. Prog. Mol. Biol. Transl Sci. 2019, 162, 93−119.
(63) Blanas, A.; Sahasrabudhe, N. M.; Rodriguez, E.; van Kooyk, Y.;
van Vliet, S. J. Fucosylated Antigens in Cancer: An Alliance toward
Tumor Progression, Metastasis, and Resistance to Chemotherapy.
Front. Oncol. 2018, 8, 39.
Journal of Proteome Research pubs.acs.org/jpr Article
https://dx.doi.org/10.1021/acs.jproteome.0c00875
J. Proteome Res. 2021, 20, 1666−1675
1675
